Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

MeSH terms

• Adenocarcinoma / drug therapy*
• Adenocarcinoma of Lung
• Afatinib
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• ErbB Receptors / genetics*
• Female
• Humans
• Lung Neoplasms / drug therapy*
• Male
• Quinazolines / therapeutic use*